Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Savant who wrote (2568)	3/18/2003 3:07:13 PM
From: Ron	Read Replies (1) \| Respond to of 3576

*DJ Geron Study Shows Telomerase Kills Cancer In All Patients 18 Mar 11:46 MENLO PARK, Calif. (Dow Jones)--Recent research results indicate that Geron Corp.'s (GERN) telomerase cancer vaccine is effective in all cancer patients, even those with tumors that don't have any known tumor-associated antigens. In a press release Tuesday, the biopharmaceutical company said telomerase is activated in all human cancer types and is therefore an attractive candidate for use as a universal cancer vaccine. Geron's study involved melanoma and colon cancer cell lines that are known to express tumor-associated antigens, as well as another line lacking any known tumor antigen. The study shows that cells genetically modified with the telomerase gene can be used to generate an immune response against cancer cells, Geron said. This response killed all three tumor cell lines in the study. A phase I study of telomerase is under way in patients with metastatic prostate cancer. Company Web site: geron.com (END) Dow Jones Newswires 03-18-03 1146ET